Assessment of Oxidative Stress in Recipients of Chronic Transfusion Therapy

Jayanta De, Kaushik Bhowmick, Utpal Chowdhury, Gopaldev Chattopadhyay, Indranil Chakraborty


Background: Excess iron deposition in chronically transfused patients may cause organ damage through generation of free radicals and resultant oxidative stress. The objective of study was to assess the oxidative stress in recipients of chronic transfusion therapy. Material and Methods: This cross-sectional study was undertaken in Department of Biochemistry, Medical College & Hospital, Kolkata, India in collaboration with Institute of Hematology & Transfusion Medicine of the same institute from May, 2007 to April, 2008. Serum Malondialdehyde, Vitamin E, erythrocyte reduced glutathione, osmotic fragility of red blood cells and serum ferritin were measured. Results: Serum malondialdehyde concentration in cases 7.87+1.44nmol/ml was significantly higher than that of controls 5.00+1.27nmol/ml (p<0.05). A significantly higher osmotic fragility in cases 4.57+0.44 g/l NaCl as compared to that of controls 4.37+ 0.46g/l NaCl was also noted (p<0.05). However, vitamin E concentration was not significantly different between these two groups in cases 10.05+2.20 mg/l as compared to controls 13.04+1.94 mg/l (p >0.05). Similarly, no significant difference was observed in erythrocyte reduced glutathione concentration in cases 3.94+1.20μmol/gHb compared to 5.80+1.08μmol/gHb in controls. The cases demonstrated significantly higher (p<0.05) serum ferritin concentration (197.98+61.65ng/ml) as compared to controls (24.51+38.47ng/ml). Conclusion: There was increased oxidative stress in cases receiving chronic transfusion therapy as signified by markers of oxidative damage, the increase in serum ferritin concentration might not have been sufficient enough to produce a concomitant decrease in serum vitamin E and reduced glutathione concentration, probably reflecting a transitory phase of ongoing cellular oxidative damage.


Oxidative stress; Transfusion therapy; Reduced glutathione; Vitamin E; Malondialdehyde; Ferritin

Full Text:



Petz LD, Swisher SN, Kleinman S, Spence RK, Strauss RG (eds). Clinical Practice of Transfusion Medicine. 3rd ed. New York: Churchill Livingstone; 1996:271-293.

Mollison PL, Engelfriet CP, Contreas M. Blood Transfusion. In: Clinical Medicine. 9th ed. Oxford: Blackwell Scientific Publications; 1993:76-147.

Jacobes A. Iron overload: clinical and pathological aspects. Semin Hematol 1977; 14(1):89-113.

Ballas SK. Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease. Semin Hematol 2001; 38: 30-6.

Crichton RR, Wilmet S, Legssyer R, Ward RJ. Molecular and cellular mechanism of iron homeostasis and toxicity in mammalian cells. J Inorg Biochem 2002; 91:9-18.

Rice-Evans CA, Diplock AT. Current status of antioxidant therapy. Free Radi Biol Med 1993; 15:77-96.

Halliwell B, Gutteridge JMC. Free radicals in Biology and Medicine. 2nd ed. Oxford: Clarendon Press; 1989: 422-38.

Pompella A, Visvikis A, Paolicchi A, De Tata V, Casini AF. The changing faces of glutathione, a cellular protagonist .Biochem Pharmacol. 2003; 66:1499-1503.

Schrier SL, Rachmilewitz EA, Mohandas N. Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: implications for differences in clinical manifestations. Blood 1989; 74:2194-2202.

Dahle LK, Hill EG, Holman RT. The thiobarbituric acid reaction and the auto oxidation of polyunsaturated fatty acid methyl esters. Arch Biochem Biophys 1962; 98:253-61.

McMurray W, Gowenlock AH. Vitamins. In: Gowenlock AH, McMurray JR, Mc Lauchlan DM. Varley’s Practical Clinical Biochemistry. 6th ed. New Delhi: CBS Publishers; 2002: 902-3.

Addison GM, Beamish MR, Hales CN, Hodgkins M, Jacobs A, Llewellin P. An immunoradiometric assay for Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. J Clin Pathol 1972; 25:326-9.

Beutler E, Duron O, Kelly B. Improved method of determination of blood glutathione. J Lab Clin Med 1963; 61: 882-8.

Parpart AK, Lorenz PB, Parpart ER. The osmotic resistance (fragility) of human red cells. J Clin Inv 1947; 26(4):636-40.

Mulligan M, Althaus B, Linder MC. Non-ferritin, non-heme iron pools in rat tissues. Int J Biochem 1986; 18(9):791-8.

Deighton N, Hider RC. Intracellular low molecular weight iron. Biochem Soc Trans. 1989; 17(3):490.

Gutteridge JMC, Rowley DA, Griffith E, Halliwell B. Low molecular weight iron complexes and oxygen radical reactions in idiopathic haemochromatosis. Clin Sci 1985; 68:463-67.

Files B, Abdullah K, Scot M, Elliott V, Winfred W, Suzanne G, et al. Longitudinal changes in ferritin during chronic transfusion: a report from the stroke prevention trial in sickle cell anemia (STOP). J Pediatr Hematol Oncol 2002; 24(4): 284-90.

Harmatz P, Butensky E, Quirol K, Williams R, Ferrel L, Moyer T, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood 2000; 96(1): 76-9.

Livea MA, Tesoriere L, Pintaudi AM, Calabrese A, Maggio A, Freisleben HJ, et al. Oxidative stress and antioxidant status in β-thalassemia major: iron overload and depletion of lipid soluble antioxidant. Blood 1996; 88(9): 3608-14.

Das N. Attenuation of oxidative stress-induced changes in thalassemic erythrocytes by vitamin E. Pol J Pharmacol 2004; 56:85-96.

Ghosh S, Bandyopadhyay S, Bhattacharya DK, Mandal C. Altered erythrocyte membrane characteristics during anemia in childhood acute lymphoblastic leukemia. Ann Hematol 2005; 84(2):76-84.

Kiessling K, Roberts N, Gibson JS, Ellory JC. A comparison in normal individuals and sickle cell patients of reduced glutathione precursors and their transport between plasma and red cells. J Hematol 2000; 1(4):243-9.


  • There are currently no refbacks.

© 2011 Gomal Journal of Medical Sciences